This company has been marked as potentially delisted and may not be actively trading.

Vaccitech (VACC) Competitors

VACC vs. SPRB, PYRGF, IBIO, HYFT, and NBRV

Should you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Spruce Biosciences (SPRB), PyroGenesis Canada (PYRGF), iBio (IBIO), MindWalk (HYFT), and Nabriva Therapeutics (NBRV).

How does Vaccitech compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

: Spruce Biosciences has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Spruce Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Spruce Biosciences N/A -203.99% -127.96%
Vaccitech -409.18% -23.41% -20.85%
: In the previous week, Spruce Biosciences had 1 more articles in the media than Vaccitech. MarketBeat recorded 1 mentions for Spruce Biosciences and 0 mentions for Vaccitech. Spruce Biosciences' average media sentiment score of 0.46 beat Vaccitech's score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the media.
Company Overall Sentiment
Spruce Biosciences Neutral
Vaccitech Neutral
: Spruce Biosciences has a beta of 3.26, suggesting that its stock price is 226% more volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500.
: Vaccitech has higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spruce Biosciences N/A N/A -$38.97M -$51.72 N/A
Vaccitech $13.42M 1.69 $5.34M -$1.43 N/A
: 91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 26.1% of Vaccitech shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by company insiders. Comparatively, 6.0% of Vaccitech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Spruce Biosciences currently has a consensus price target of $190.60, suggesting a potential upside of 233.24%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Spruce Biosciences is more favorable than Vaccitech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spruce Biosciences
1 Sell rating(s)
2 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.50
Vaccitech
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-203.99%	-127.96%
Vaccitech	-409.18%	-23.41%	-20.85%

Company	Overall Sentiment
Spruce Biosciences	Neutral
Vaccitech	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	N/A	N/A	-$38.97M	-$51.72	N/A
Vaccitech	$13.42M	1.69	$5.34M	-$1.43	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vaccitech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Spruce Biosciences beats Vaccitech on 8 of the 15 factors compared between the two stocks.

How does Vaccitech compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and Vaccitech (NASDAQ:VACC) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

: PyroGenesis Canada has a net margin of -115.14% compared to Vaccitech's net margin of -409.18%. PyroGenesis Canada's return on equity of 0.00% beat Vaccitech's return on equity.
Company Net Margins Return on Equity Return on Assets
PyroGenesis Canada -115.14% N/A -60.81%
Vaccitech -409.18% -23.41% -20.85%
: In the previous week, PyroGenesis Canada had 2 more articles in the media than Vaccitech. MarketBeat recorded 2 mentions for PyroGenesis Canada and 0 mentions for Vaccitech. PyroGenesis Canada's average media sentiment score of 0.00 equaled Vaccitech'saverage media sentiment score.
Company Overall Sentiment
PyroGenesis Canada Neutral
Vaccitech Neutral
: PyroGenesis Canada has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, meaning that its stock price is 140% less volatile than the S&P 500.
: Vaccitech has higher revenue and earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PyroGenesis Canada $9.14M 7.02 -$21.12M -$0.05 N/A
Vaccitech $13.42M 1.69 $5.34M -$1.43 N/A
: 0.0% of PyroGenesis Canada shares are held by institutional investors. Comparatively, 26.1% of Vaccitech shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by company insiders. Comparatively, 6.0% of Vaccitech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Vaccitech	-409.18%	-23.41%	-20.85%

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Vaccitech	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	7.02	-$21.12M	-$0.05	N/A
Vaccitech	$13.42M	1.69	$5.34M	-$1.43	N/A

Summary

PyroGenesis Canada beats Vaccitech on 7 of the 12 factors compared between the two stocks.

How does Vaccitech compare to iBio?

Vaccitech (NASDAQ:VACC) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

: 26.1% of Vaccitech shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 6.0% of Vaccitech shares are held by company insiders. Comparatively, 2.8% of iBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: iBio has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat iBio's return on equity.
Company Net Margins Return on Equity Return on Assets
Vaccitech -409.18% -23.41% -20.85%
iBio N/A -71.26% -57.92%
: In the previous week, iBio had 2 more articles in the media than Vaccitech. MarketBeat recorded 2 mentions for iBio and 0 mentions for Vaccitech. iBio's average media sentiment score of 1.66 beat Vaccitech's score of 0.00 indicating that iBio is being referred to more favorably in the news media.
Company Overall Sentiment
Vaccitech Neutral
iBio Very Positive
: Vaccitech has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500. Comparatively, iBio has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.
: iBio has a consensus price target of $4.75, suggesting a potential upside of 189.99%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Vaccitech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaccitech
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
iBio
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

3 Strong Buy rating(s)
3.17
: Vaccitech has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vaccitech $13.42M 1.69 $5.34M -$1.43 N/A
iBio $400K 147.99 -$18.38M -$1.00 N/A

Company	Net Margins	Return on Equity	Return on Assets
Vaccitech	-409.18%	-23.41%	-20.85%
iBio	N/A	-71.26%	-57.92%

Company	Overall Sentiment
Vaccitech	Neutral
iBio	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccitech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccitech	$13.42M	1.69	$5.34M	-$1.43	N/A
iBio	$400K	147.99	-$18.38M	-$1.00	N/A

Summary

iBio beats Vaccitech on 10 of the 17 factors compared between the two stocks.

How does Vaccitech compare to MindWalk?

Vaccitech (NASDAQ:VACC) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

: 26.1% of Vaccitech shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 6.0% of Vaccitech shares are held by company insiders. Comparatively, 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: MindWalk has a net margin of -66.79% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat MindWalk's return on equity.
Company Net Margins Return on Equity Return on Assets
Vaccitech -409.18% -23.41% -20.85%
MindWalk -66.79% -69.37% -39.74%
: In the previous week, Vaccitech's average media sentiment score of 0.00 equaled MindWalk'saverage media sentiment score.
Company Overall Sentiment
Vaccitech Neutral
MindWalk Neutral
: Vaccitech has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500. Comparatively, MindWalk has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.
: MindWalk has a consensus price target of $5.00, suggesting a potential upside of 301.61%. Given MindWalk's stronger consensus rating and higher probable upside, analysts clearly believe MindWalk is more favorable than Vaccitech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaccitech
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
MindWalk
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

1 Strong Buy rating(s)
2.60
: Vaccitech has higher earnings, but lower revenue than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vaccitech $13.42M 1.69 $5.34M -$1.43 N/A
MindWalk $17.59M 3.27 -$21.69M -$0.20 N/A

Company	Net Margins	Return on Equity	Return on Assets
Vaccitech	-409.18%	-23.41%	-20.85%
MindWalk	-66.79%	-69.37%	-39.74%

Company	Overall Sentiment
Vaccitech	Neutral
MindWalk	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccitech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccitech	$13.42M	1.69	$5.34M	-$1.43	N/A
MindWalk	$17.59M	3.27	-$21.69M	-$0.20	N/A

Summary

MindWalk beats Vaccitech on 10 of the 15 factors compared between the two stocks.

How does Vaccitech compare to Nabriva Therapeutics?

Vaccitech (NASDAQ:VACC) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

: Vaccitech has higher earnings, but lower revenue than Nabriva Therapeutics. Vaccitech is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vaccitech $13.42M 1.69 $5.34M -$1.43 N/A
Nabriva Therapeutics $35.59M 0.00 -$57.19M -$19.20 N/A
: In the previous week, Nabriva Therapeutics had 1 more articles in the media than Vaccitech. MarketBeat recorded 1 mentions for Nabriva Therapeutics and 0 mentions for Vaccitech. Vaccitech's average media sentiment score of 0.00 equaled Nabriva Therapeutics'average media sentiment score.
Company Overall Sentiment
Vaccitech Neutral
Nabriva Therapeutics Neutral
: Nabriva Therapeutics has a net margin of -148.11% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Nabriva Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Vaccitech -409.18% -23.41% -20.85%
Nabriva Therapeutics -148.11% -365.53% -135.81%
: Vaccitech has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
: 26.1% of Vaccitech shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 6.0% of Vaccitech shares are owned by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccitech	$13.42M	1.69	$5.34M	-$1.43	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

Company	Overall Sentiment
Vaccitech	Neutral
Nabriva Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Vaccitech	-409.18%	-23.41%	-20.85%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Summary

Vaccitech beats Nabriva Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Vaccitech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VACC vs. The Competition

Export

Metric	Vaccitech	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.71M	$901.24M	$6.20B	$12.23B
Dividend Yield	N/A	4.84%	2.78%	5.25%
P/E Ratio	-0.41	1.72	28.72	27.04
Price / Sales	1.69	120.73	529.04	75.91
Price / Cash	19.30	20.07	43.30	53.97
Price / Book	0.09	7.67	9.85	6.85
Net Income	$5.34M	-$4.80M	$3.55B	$333.00M

Vaccitech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VACC Vaccitech	N/A	$0.59 +8.9%	N/A	-41.1%	$22.71M	$13.42M	N/A	33
SPRB Spruce Biosciences	2.3685 of 5 stars	$54.37 flat	$203.25 +273.8%	+934.7%	$74.49M	$4.91M	N/A	20
PYRGF PyroGenesis Canada	N/A	$0.30 flat	N/A	-8.7%	$61.51M	$9.14M	N/A	90	News Coverage Gap Down
IBIO iBio	4.3084 of 5 stars	$1.68 flat	$4.75 +182.7%	N/A	$60.72M	$400K	N/A	100	News Coverage Gap Up
HYFT MindWalk	2.1346 of 5 stars	$1.22 flat	$5.00 +309.8%	N/A	$56.32M	$17.59M	N/A	80	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VACC) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaccitech (VACC) Competitors

VACC vs. SPRB, PYRGF, IBIO, HYFT, and NBRV

How does Vaccitech compare to Spruce Biosciences?

Summary

How does Vaccitech compare to PyroGenesis Canada?

Summary

How does Vaccitech compare to iBio?

Summary

How does Vaccitech compare to MindWalk?

Summary

How does Vaccitech compare to Nabriva Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VACC vs. The Competition

Vaccitech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaccitech (VACC) Competitors

VACC vs. SPRB, PYRGF, IBIO, HYFT, and NBRV

How does Vaccitech compare to Spruce Biosciences?

Summary

How does Vaccitech compare to PyroGenesis Canada?

Summary

How does Vaccitech compare to iBio?

Summary

How does Vaccitech compare to MindWalk?

Summary

How does Vaccitech compare to Nabriva Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VACC vs. The Competition

Vaccitech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools